Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EZZ Life Science Holdings Limited (EZZ.AX)
Lidcombe, NSW, AU
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territories. The company's operations are divided into two distinct segments: 'Brought in Lines' and 'Company Owned products.' EZZ is actively involved in the wholesale supply of its EAORON-branded skincare portfolio, distributing it to pharmacies, major supermarkets, specialist retailers, and general grocery stores. Furthermore, the company designs, develops, manufactures, and markets a comprehensive selection of consumer health products under its own EZZ brand. This extensive offering includes vitamins, dietary supplements, sports nutrition, weight management and wellbeing solutions, traditional herbal remedies, and paediatric lines. These EZZ-branded items are sold directly to consumers via its e-commerce platforms and various retail stores, notably Tmall Global. Founded in 2015, EZZ Life Science Holdings Limited maintains its corporate headquarters in Silverwater, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+0.7% Q4'25: +14.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-6.3% Q4'25: -150.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+3.6% Q4'25: -22.3% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+15.8% ★ Q4'25: -0.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+89.3% ★ Q4'25: -1.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+7.4% Q4'25: +10.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.03× ★ Q4'25: 0.23× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
15.02M
est: 15.00M (+0.1%)
|
37.14M
est: 28.54M (+30.1%)
|
66.44M
est: 44.71M (+48.6%)
|
66.87M
est: 76.40M (-12.5%)
|
95.50M
95.50M – 95.50M
+25.0% YoY
|
105.10M
105.10M – 105.10M
+10.1% YoY
|
| EBITDA |
1.90M
est: 2.14M (-11.3%)
|
5.09M
est: 4.08M (+24.8%)
|
10.38M
est: 6.39M (+62.3%)
|
11.10M
est: 10.92M (+1.6%)
|
13.65M
13.65M – 13.65M
+25.0% YoY
|
15.03M
15.03M – 15.03M
+10.1% YoY
|
| EBIT |
1.78M
est: 2.05M (-12.9%)
|
4.91M
est: 3.90M (+26.0%)
|
9.98M
est: 6.11M (+63.5%)
|
10.59M
est: 10.43M (+1.5%)
|
13.04M
13.04M – 13.04M
+25.0% YoY
|
14.35M
14.35M – 14.35M
+10.1% YoY
|
| Net Income |
1.31M
est: 1.62M (-18.9%)
|
3.63M
est: 2.64M (+37.7%)
|
6.96M
est: 2.91M (+139.0%)
|
6.73M
est: 7.08M (-4.9%)
|
9.30M
9.30M – 9.30M
+31.4% YoY
|
11.15M
11.15M – 11.15M
+19.9% YoY
|
| SGA |
3.86M
est: 7.02M (-44.9%)
|
21.70M
est: 13.36M (+62.5%)
|
38.49M
est: 20.92M (+84.0%)
|
35.87M
est: 35.75M (+0.3%)
|
44.69M
44.69M – 44.69M
+25.0% YoY
|
49.18M
49.18M – 49.18M
+10.1% YoY
|
| EPS |
0.03
est: 0.04 (-11.7%)
|
0.09
est: 0.06 (+49.1%)
|
0.16
est: 0.06 (+154.0%)
|
0.15
est: 0.15 (-2.0%)
|
0.20
0.20 – 0.20
+31.4% YoY
|
0.24
0.24 – 0.24
+19.9% YoY
|
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Qin | Co-founder, Chief Operating Officer, Chief Executive Officer & Executive Director | 278.8K | male |
| Glenn Cross | Chief Strategy Officer | 118.8K | — |
| Anthony Guarna | Chief Financial Officer | 103.0K | male |
| Christine Chen | Executive Director | — | female |
| James Hudson | Director of Corporate Affairs | — | male |
| Jay Stephenson | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EZZ.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
